Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study

NCT03748303 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT03748303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03748303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study
Lead sponsor
University of Arizona
Phase
Phase 1
Overall status
Terminated
Start date
October 1, 2019
Completion date
December 21, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia